These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 24709005)

  • 21. Proton pump inhibitor responders who are not confirmed as GERD patients with impedance and pH monitoring: who are they?
    de Bortoli N; Martinucci I; Savarino E; Bellini M; Bredenoord AJ; Franchi R; Bertani L; Furnari M; Savarino V; Blandizzi C; Marchi S
    Neurogastroenterol Motil; 2014 Jan; 26(1):28-35. PubMed ID: 23992024
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impairment of chemical clearance and mucosal integrity distinguishes hypersensitive esophagus from functional heartburn.
    Frazzoni M; de Bortoli N; Frazzoni L; Furnari M; Martinucci I; Tolone S; Farioli A; Marchi S; Fuccio L; Savarino V; Savarino E
    J Gastroenterol; 2017 Apr; 52(4):444-451. PubMed ID: 27241210
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Manually calculated oesophageal bolus clearance time increases in parallel with reflux severity at impedance-pH monitoring.
    de Bortoli N; Martinucci I; Savarino EV; Frazzoni M; Tutuian R; Tolone S; Piaggi P; Furnari M; Russo S; Bertani L; Macchia L; Savarino V; Marchi S
    Dig Liver Dis; 2015 Dec; 47(12):1027-32. PubMed ID: 26362613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The extent of oesophageal acid exposure overlap among the different gastro-oesophageal reflux disease groups.
    Shapiro M; Green C; Faybush EM; Esquivel RF; Fass R
    Aliment Pharmacol Ther; 2006 Jan; 23(2):321-9. PubMed ID: 16393313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of esophageal impedance/pH monitoring in patients with refractory gastroesophageal reflux disease, on and off therapy.
    Pritchett JM; Aslam M; Slaughter JC; Ness RM; Garrett CG; Vaezi MF
    Clin Gastroenterol Hepatol; 2009 Jul; 7(7):743-8. PubMed ID: 19281866
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Race affects healing of erosive oesophagitis in patients treated with proton pump inhibitors.
    Sharma P; Johnson DA; Monyak JT; Illueca M
    Aliment Pharmacol Ther; 2011 Aug; 34(4):487-93. PubMed ID: 21682754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of Reflux in the Pathogenesis of Eosinophilic Esophagitis: Comprehensive Appraisal With Off- and On PPI Impedance-pH Monitoring.
    Frazzoni M; Penagini R; Frazzoni L; de Bortoli N; Mauro A; Tolone S; Bertani H; Marsico M; Marocchi M; Marchi S; Conigliaro R; Savarino E
    Am J Gastroenterol; 2019 Oct; 114(10):1606-1613. PubMed ID: 31449157
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of risk factors and clinical responses to proton pump inhibitors in patients with erosive oesophagitis and non-erosive reflux disease.
    Lee ES; Kim N; Lee SH; Park YS; Kim JW; Jeong SH; Lee DH; Jung HC; Song IS
    Aliment Pharmacol Ther; 2009 Jul; 30(2):154-64. PubMed ID: 19392871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of Vonoprazan, a Novel Potassium-Competitive Acid Blocker, in Patients with Proton Pump Inhibitor-Refractory Acid Reflux.
    Akiyama J; Hosaka H; Kuribayashi S; Moriyasu S; Hisada Y; Okubo H; Watanabe K; Imbe K; Nagata N; Kojima Y; Yokoi C; Uemura N; Shimoyama Y; Kawamura O; Yamada M; Kusano M
    Digestion; 2020; 101(2):174-183. PubMed ID: 30897577
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Esophageal acid exposure decreases intraluminal baseline impedance levels.
    Kessing BF; Bredenoord AJ; Weijenborg PW; Hemmink GJ; Loots CM; Smout AJ
    Am J Gastroenterol; 2011 Dec; 106(12):2093-7. PubMed ID: 21844921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Applying Lyon Consensus criteria in the work-up of patients with proton pump inhibitory-refractory heartburn.
    Frazzoni M; Frazzoni L; Ribolsi M; Bortoli N; Tolone S; Russo S; Conigliaro R; Penagini R; Fuccio L; Zagari RM; Savarino E
    Aliment Pharmacol Ther; 2022 Jun; 55(11):1423-1430. PubMed ID: 35229321
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Symptom association probability does not reliably distinguish functional heartburn from reflux hypersensitivity.
    Choksi Y; Slaughter JC; Sharda R; Higginbotham T; Lal P; Vaezi MF
    Aliment Pharmacol Ther; 2018 Apr; 47(7):958-965. PubMed ID: 29372566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overweight is a risk factor for both erosive and non-erosive reflux disease.
    Savarino E; Zentilin P; Marabotto E; Bonfanti D; Inferrera S; Assandri L; Sammito G; Gemignani L; Furnari M; Dulbecco P; Savarino V
    Dig Liver Dis; 2011 Dec; 43(12):940-5. PubMed ID: 21944835
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn.
    DeVault KR
    Aliment Pharmacol Ther; 2006 Mar; 23 Suppl 1():33-9. PubMed ID: 16483268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Determinants of gastro-oesophageal reflux perception in patients with persistent symptoms despite proton pump inhibitors.
    Zerbib F; Duriez A; Roman S; Capdepont M; Mion F
    Gut; 2008 Feb; 57(2):156-60. PubMed ID: 17951358
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response of eosinophilic oesophagitis to proton pump inhibitors is associated with impedance-pH parameters implying anti-reflux mechanism of action.
    Frazzoni M; Frazzoni L; De Bortoli N; Russo S; Tolone S; Arsiè E; Conigliaro R; Penagini R; Savarino E
    Aliment Pharmacol Ther; 2021 Jun; 53(11):1183-1189. PubMed ID: 33857331
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reflux parameters as modified by EsophyX or laparoscopic fundoplication in refractory GERD.
    Frazzoni M; Conigliaro R; Manta R; Melotti G
    Aliment Pharmacol Ther; 2011 Jul; 34(1):67-75. PubMed ID: 21539587
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Refractory GERD: increased body mass index is associated with persisting acid exposure but not hypersensitive esophagus or functional heartburn.
    Viazis N; Karamanolis GP; Anastasiou J; Keyoglou A; Vlachogiannakos J; Ladas SD; Karamanolis DG
    Eur J Gastroenterol Hepatol; 2013 Dec; 25(12):1450-5. PubMed ID: 24047861
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The added value of impedance-pH monitoring to Rome III criteria in distinguishing functional heartburn from non-erosive reflux disease.
    Savarino E; Marabotto E; Zentilin P; Frazzoni M; Sammito G; Bonfanti D; Sconfienza L; Assandri L; Gemignani L; Malesci A; Savarino V
    Dig Liver Dis; 2011 Jul; 43(7):542-7. PubMed ID: 21376679
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reflux patterns in patients with short-segment Barrett's oesophagus: a study using impedance-pH monitoring off and on proton pump inhibitor therapy.
    Frazzoni M; Savarino E; Manno M; Melotti G; Mirante VG; Mussetto A; Bertani H; Manta R; Conigliaro R
    Aliment Pharmacol Ther; 2009 Sep; 30(5):508-15. PubMed ID: 19519732
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.